Objective To evaluate the efficacy and safety of disodium cantharidinate injection combined with transcatheter arterial chemoembolization(TACE) compared with TCAE alone in the treatment of hepatocellular carcinoma(HCC) by meta-analysis.Methods Databases of Pubmed, CNKI,Wangfang and VIP were searched electronically, and the randomized controlled trials about disodium cantharidinate injection combined with TACE in the treatment of HCC were included.Meta-analyses were conducted after the quality of the included studies was assessed.Results Seven eligible studies that included a total of 562 HCC patients were identified in the present meta-analysis.The combined results showed that disodium cantharidinate injection combined with TACE in the treatment of HCC, compared with TACE alone, could increase effective rate ( RR =1.31, 95%CI 1.10-1.56) and clinical benefit rate (RR =1.20, 95%CI 1.04 -1.39), improve the life quality (RR =1.60, 95%CI 1.26 -2.03) and improved the 1, 2 year survival (RR =1.57 with 95%CI 1.28 -1.93 and RR =2.08 with 95%CI 1.46 -2.97, respectively).Conclusion Meta-analysis indicates that the efficacy of disodium cantharidinate injection combined with TACE is superior to TACE alone for the patients with HCC.

OBJECTIVE:To evaluate the effectiveness and safety of Shenqi fuzheng injection assisting TACE in the adjuvant treatment of primary liver carcinoma,and to provide evidence-based reference.METHODS:Retrieved from CJFD,Wanfang database,VIP and PubMed,randomized controlled trials (RCTs) about Shenqi fuzheng injection assisting TACE (trial group) vs.TACE alone (control group) in the treatment of primary liver carcinoma were collected.Meta-analysis was performed by using Stata 12.0 software after data extraction and quality evaluation according to improved Jadad scale.RESULTS:A total of 8 RCTs were included,involving 527 patients.Results of Meta-analysis showed that there was no statistical significance in response rate [RR=1.19,95％CI(0.97,1.46),P=0.091] and clinical benefit rate [RR=1.16,95％CI(0.90,1.48),P=0.251] of 2 groups.The rate of life quality improvement in trial group was significantly higher than control group [RR=2.26,95 ％ CI (1.64,3.10),P=0.001],while the incidence of above middle fever [RR=0.74,95％ CI (0.63,0.88),P=0.001],gastrointestinal reaction [RR=0.52,95％ CI (0.32,0.85),P=0.010] and leucocyte reduction rate [RR=0.75,95％ CI (0.62,0.92),P=0.005],were significantly lower than control group,with statistical significance.CONCLUSIONS:Shenqi fuzheng injection assisting TACE for primary liver carcinoma cannot improve therapeutic efficacy but improve the quality of life and reduce the incidence of gastrointestinal reaction and leucocyte reduction.